About this item:

25 Views | 38 Downloads

Author Notes:

Correspondence: piotr_smolewski@wp.pl; Tel.: +42-689-51-91; Fax: +42-689-51-92

Aleksandra Mędra designed the research, performed the research, analyzed the data and wrote the paper.

Magdalena Witkowska analyzed the data and wrote the paper.

Agata Majchrzak performed the research and analyzed the data.

Barbara Cebula-Obrzut performed the research and analyzed the data.

Michael Y. Bonner contributed vital new reagents or analytical tools.

Tadeusz Robak designed the research and wrote the paper.

Jack L. Arbiser contributed vital new reagents or analytical tools and wrote the paper.

Piotr Smolewski designed the research, performed the research, analyzed the data and wrote the paper.

The authors declare no conflict of interest.

Subjects:

Research Funding:

The study was supported in part by grant funding from The Medical University of Lodz, Poland: Grants No. 502-03/8-093-01/502-64-032 and No. 503/8-093-01/503-01; the Margolis Family Foundation; the Rabinowitch-Davis Foundation; the Minsk Foundation; and NIH RO1AR47901.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Physical Sciences
  • Biochemistry & Molecular Biology
  • Chemistry, Multidisciplinary
  • Chemistry
  • honokiol analogues
  • CLL
  • ALL
  • BL
  • DLBCL
  • MM
  • HONOKIOL INDUCES APOPTOSIS
  • CHRONIC LYMPHOCYTIC-LEUKEMIA
  • IN-VITRO
  • PHENOLIC CONSTITUENTS
  • NATURAL-PRODUCT
  • CYTOCHROME-C
  • CH27 CELLS
  • MAGNOLOL
  • ACTIVATION
  • CANCER

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies

Tools:

Journal Title:

Molecules

Volume:

Volume 21, Number 8

Publisher:

, Pages 995-995

Type of Work:

Article | Final Publisher PDF

Abstract:

Honokiol and triphenylmethanes are small molecules with anti-tumor properties. Recently, we synthesized new honokiol analogues (HAs) that possess common features of both groups. We assessed the anti-tumor effectiveness of HAs in B-cell leukemia/lymphoma cells, namely in chronic lymphocytic leukemia (CLL) cells ex vivo and in pre-B-cell acute lymphoblastic leukemia (Nalm-6), Burkitt lymphoma (BL; Raji), diffuse large B-cell lymphoma (DLBCL; Toledo) and multiple myeloma (MM; RPMI 8226) cell lines. Four of these compounds appeared to be significantly active against the majority of cells examined, with no significant impact on healthy lymphocytes. These active HAs induced caspase-dependent apoptosis, causing significant deregulation of several apoptosis-regulating proteins. Overall, these compounds downregulated Bcl-2 and XIAP and upregulated Bax, Bak and survivin proteins. In conclusion, some of the HAs are potent tumor-selective inducers of apoptosis in ex vivo CLL and in BL, DLBCL and MM cells in vitro. Further preclinical studies of these agents are recommended.

Copyright information:

© 2016 by the authors; licensee MDPI, Basel, Switzerland.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote